A Phase 2a, Randomized, Open-Label Study to Determine the Optimal Dose and Evaluate the Safety, Tolerability, and Pharmacokinetics of Progerinin in Patients with Hutchinson-Gilford Progeria Syndrome (HGPS)
Latest Information Update: 20 Jan 2025
Price :
$35 *
At a glance
- Drugs Progerinin (Primary) ; Lonafarnib
- Indications Progeria
- Focus Adverse reactions; Pharmacokinetics
- Sponsors PRG Science & Technology
- 20 Jan 2025 New trial record